KeyBanc raised the firm’s price target on ResMed (RMD) to $266 from $251 and keeps an Overweight rating on the shares following the Q1 earnings report. KeyBanc was encouraged by the broad ...

Baird analyst David Rescott raised the firm’s price target on ResMed (RMD) to $283 from $280 and keeps an Outperform rating on the shares. The firm said they’re increasingly confident in ...

Sleep and respiratory disorders sector of the medical device industry ("Sleep and Respiratory Care') and the supply of business management software as a service to out-of-hospital health providers ...

Pre-earnings options volume in ResMed (RMD) is 3.5x normal with puts leading calls 7:5. Implied volatility suggests the market is anticipating a move near 6.9%, or $16.63, after results are released.

Although the Resmed share price is not as good value as it was six months ago, the ASX healthcare share seems to have a promising future.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The S9 Elite™ is a whisper quiet, elegant and comfortable therapy system for the treatment of Obstructive Sleep Apnoea (OSA). The S9 Elite provides Continuous Positive Airway Pressure (CPAP ...

ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.